going it alone would be a big mistake in my opinion.

we have a great molecule, but are in the current predicament because of the things we don't have: basically the experience, know-how, and connections to navigate the process of turning a great molecule into a revenue producing drug. and until that great molecule is a revenue producing drug, it remains "gold in the mine" as they say.

i hope 2022 is the year we partner up with some big guns to get this across the finish line!